Serum levels of cell adhesion molecules in patients with neuromyelitis optica spectrum disorder

Chang, Bao‐Luen; Ro, Long‐Sun; Chen, Chiung‐Mei; Lo, Yu‐Lun; Lyu, Rong‐Kuo; Kuo, Hung‐Chou; Liao, Ming‐Feng; Chang, Chun‐Wei; Chang, Hong‐Shiu; Huang, Chien-Yiu; Wu, Yih‐Ru; Chu, Chun‐Che; Weng, Yi‐Ching; Chang, Kuo‐Hsuan

doi:10.1002/acn3.51167

Cited by 7 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in our cohort there were no statistical differences in sVCAM-1 serum levels, which were the highest in HC, followed by SLE and MS, and the lowest in NMOsd. These results are different to those from the above-mentioned studies [31,32]. Such differences could be due to various factors.…”

Section: Discussioncontrasting

confidence: 99%

“…In our study, we observed that serum sPECAM-1 concentrations were significantly lower in patients with NMOsd than with MS and in the HC. This was in accordance with the findings published by Chang et al [31]. However, our results differed for sICAM-1 and sVCAM-1, in that we found higher concentrations of VCAM-1 in NMOsd than in MS and HC, and higher ICAM-1 levels in NMOsd than in HC (but not in MS) [31].…”

Section: Discussionsupporting

confidence: 92%

“…This was in accordance with the findings published by Chang et al [31]. However, our results differed for sICAM-1 and sVCAM-1, in that we found higher concentrations of VCAM-1 in NMOsd than in MS and HC, and higher ICAM-1 levels in NMOsd than in HC (but not in MS) [31]. Uzawa et al showed that sICAM-1 serum levels were elevated in patients with NMO compared to MS [32].…”

Section: Discussionsupporting

confidence: 91%

“…The impact of treatment on adhesion molecules levels was analysed in previous studies which showed that sVCAM-1 serum levels decrease in patients with RRMS after intravenous methyloprednisolone or that sVCAM-1 serum levels increase in MS patients treated with beta-interferon, which in turn correlated with a decrease in MRI activity [34,35]. Secondly, our patients were in remission, while Chang et al evaluated patients within two weeks of symptoms onset or acute relapse [31]. Levels of adhesion molecules might depend on disease activity, as in MS patients serum levels of sICAM-1, sVCAM-1 or PECAM-1 correlate with the presence of gadolinium-enhancing lesions on MRI [15,[35][36][37][38][39].…”

Section: Discussionmentioning

confidence: 92%

“…Such differences could be due to various factors. Firstly, we tested MS patients treated with beta-interferons or glatiramer acetate (which were, at the time, the most common first-line treatments in Polish MS patients [33]), oral steroids and/or azathioprine (NMOsd and NPSLE), and/or other immunosuppressants (NPSLE), while Chang et al evaluated patients before therapy with steroids, immunoglobulins or plasmapheresis [31]. The impact of treatment on adhesion molecules levels was analysed in previous studies which showed that sVCAM-1 serum levels decrease in patients with RRMS after intravenous methyloprednisolone or that sVCAM-1 serum levels increase in MS patients treated with beta-interferon, which in turn correlated with a decrease in MRI activity [34,35].…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus

Jasiak-Zatońska

Pietrzak

Wyciszkiewicz

et al. 2022

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Aim of the study. To assess differences in BBB damage profiles by measuring serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and S100 calcium-binding protein B (S100B) in relapsing-remitting multiple sclerosis (RRMS), neuromyelitis optica spectrum disorders (NMOsd), and neuropsychiatric systemic lupus erythematosus (NPSLE) patients.Clinical rationale for the study. Blood-brain-barrier (BBB) disruption is one of the key pathological processes involved in various demyelinating diseases of the central nervous system (CNS) and is associated with shedding of cell adhesion molecules and S100B into the serum compartment. Therefore, making an assessment of serum levels of the above-mentioned molecules could provide information about disease pathogenesis, severity of BBB disruption, and disease activity.Material and methods. We recruited 42 RRMS, 19 NMOsd and 35 NPSLE patients. Subjects were treated with beta-interferons or glatiramer acetate (RRMS), oral steroids and/or azathioprine (NMOsd, NPSLE), other immunosuppressants (NPSLE), or antimalarials (NPSLE). The clinical condition of the patients was assessed using the Kurtzke Expanded Disability Status Scale for MS and NMOsd, and the Systemic Lupus Erythematosus Disease Activity Index for NPSLE. Serum levels of sVCAM-1, sPECAM-1, sICAM-1 and S100B were determined using enzyme-linked immunosorbent assay (ELISA).Results. We found the lowest levels of sPECAM-1, sICAM-1 and S100B in sera from NMOsd patients. The highest levels of sPE-CAM-1 and sICAM-1 were observed in NPSLE, and in NPSLE and MS, respectively. There were no statistically significant differences in sVCAM-1 levels between the examined groups. In MS and NMOsd, there was a negative correlation between the EDSS score and the following molecules: sPECAM-1, sICAM-1 and S100B.Conclusions and clinical implications. We conclude that there is a different profile of blood-brain-barrier disruption reflected by cell adhesion molecules shedding in the spectrum of autoimmune CNS disorders with disseminated white matter lesions. These molecules could become new biomarkers to be used in CNS demyelinating diseases differential diagnoses and monitoring disease activity, but further studies on larger groups of patients are necessary.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 92%